Literature DB >> 10834866

A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature.

S F Sørensen1, O Slot, N Tvede, J Petersen.   

Abstract

OBJECTIVE: To test the usefulness of the Chapel Hill nomenclature, supplemented with surrogate parameters, as diagnostic criteria for primary vasculitides.
METHODS: To prospectively evaluate vasculitis patients according to a standardised clinical and para-clinical programme. In accordance with the Chapel Hill publication surrogate parameters were used: proteinuria, haematuria and red blood cell casts (glomerulonephritis), angiographic or ultrasonic demonstration of aneurysms or stenoses (arteritis), radiological lung infiltrates or cavitations of more than one month's duration (granuloma in the lungs), bloody nasal discharge or crusts, chronic sinusitis, otitis and/or mastoiditis, bone and/or cartilage destruction, and acute hearing loss (granuloma in upper airways).
RESULTS: The following entities were diagnosed: giant cell arteritis (n=14), Takayasu arteritis (n=1), polyarteritis nodosa (n=2), Wegener's granulomatosis (n=27), Churg-Strauss syndrome (n=2), microscopic polyangiitis (n=12), Henoch-Schönlein purpura (n=2), cutaneous leucocytoclastic angiitis (n=37), and secondary vasculitis (n=21). Giant cell arteritis and cutaneous leucocytoclastic angiitis were in all cases diagnosed by biopsy. Using the Chapel Hill nomenclature supplemented with surrogate parameters, only 8 of 27 patients were diagnosed with Wegener's granulomatosis, and 3 of 12 cases with microscopic polyangiitis. The number of patients in the remaining diagnostic entities were considered to few to evaluate.
CONCLUSIONS: The Chapel Hill nomenclature, supplemented with surrogate parameters, failed to act as diagnostic criteria in Wegener's granulomatosis and microscopic polyangiitis. The following diagnostic criteria are proposed for Wegener's granulomatosis: (1) Biopsy or surrogate parameter for granulomatous inflammation in the respiratory system and (2) Biopsy verified necrotising vasculitis in small to medium sized vessels or biopsy/surrogate parameter for glomerulonephritis or positive PR3-ANCA test and (3) Lack of eosinophilia in blood and biopsy samples. The following diagnostic criteria are proposed for microscopic polyangiitis: (1) Biopsy verified necrotising vasculitis in small vessels and/or glomerulonephritis with few or no immune deposits and (2) Involvement of more than one organ system as indicated by biopsy verified vasculitis in small to medium sized vessels or surrogate parameter for glomerulonephritis and (3) Lack of biopsy and surrogate parameter for granulomatous inflammation in the respiratory system. Using these criteria all Wegener's patients and 9 of 12 patients with microscopic polyangiitis could be diagnosed.

Entities:  

Mesh:

Year:  2000        PMID: 10834866      PMCID: PMC1753166          DOI: 10.1136/ard.59.6.478

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  Periarteritis nodosa; a critical review.

Authors:  P M ZEEK
Journal:  Am J Clin Pathol       Date:  1952-08       Impact factor: 2.493

2.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

3.  Classification and epidemiology of systemic vasculitis.

Authors:  D G Scott; R A Watts
Journal:  Br J Rheumatol       Date:  1994-10

4.  Cutaneous vasculitis in a defined population--clinical and epidemiological associations.

Authors:  R A Watts; V A Jolliffe; C E Grattan; J Elliott; M Lockwood; D G Scott
Journal:  J Rheumatol       Date:  1998-05       Impact factor: 4.666

Review 5.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

Review 6.  Small-vessel vasculitis.

Authors:  J C Jennette; R J Falk
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

7.  Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis.

Authors:  R A Watts; V A Jolliffe; D M Carruthers; M Lockwood; D G Scott
Journal:  Arthritis Rheum       Date:  1996-07

8.  The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications.

Authors:  B A Bengtsson; B E Malmvall
Journal:  Arthritis Rheum       Date:  1981-07

9.  Epidemiology of systemic vasculitis: changing incidence or definition?

Authors:  R A Watts; D M Carruthers; D G Scott
Journal:  Semin Arthritis Rheum       Date:  1995-08       Impact factor: 5.532

10.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11
View more
  28 in total

Review 1.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

Review 2.  ANCA-associated small vessel vasculitis: clinical and therapeutic advances.

Authors:  Niveditha Mohan; Gail S Kerr
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

Review 3.  The lung in systemic vasculitis: radiological patterns and differential diagnosis.

Authors:  Beatrice Feragalli; Cesare Mantini; Marco Sperandeo; Michele Galluzzo; Giovanni Belcaro; Armando Tartaro; Antonio R Cotroneo
Journal:  Br J Radiol       Date:  2016-02-15       Impact factor: 3.039

Review 4.  [Early diagnosis of vasculitides].

Authors:  B Hellmich; P Lamprecht; P M Aries; W L Gross
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 5.  Classification of the vasculitides: are they clinically useful?

Authors:  Ana M Bertoli; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

Review 6.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

7.  How could we make a diagnosis of Wegener's granulomatosis?

Authors:  Shuang Ye; Cheng-de Yang
Journal:  Clin Rheumatol       Date:  2006-01-21       Impact factor: 2.980

8.  Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.

Authors:  Achille Aouba; Christian Pagnoux; Boris Bienvenu; Alfred Mahr; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-12       Impact factor: 8.667

9.  Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology.

Authors:  Sevil Kamali; Bahar Artim-Esen; Burak Erer; Lutfiye Ozdener; Ahmet Gul; Lale Ocal; Orhan Aral; Murat Inanc
Journal:  Clin Rheumatol       Date:  2011-08-04       Impact factor: 2.980

Review 10.  Classification of ANCA-associated vasculitis.

Authors:  Irfan Khan; Richard A Watts
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.